Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1800)	8/20/2007 12:50:38 PM
From: tuck	Respond to of 2240

>>CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells] Oldie (last summer), but relevant . . . "Therefore, additional conventional or immune-based interventions aiming at enhancing antigen presentation, such as the coadministration of cellular vaccines capable of selectively expanding tumor-reactive Teffs, are likely to be an essential component of antitumor therapies incorporating anti-CTLA4." jci.org Full text freebie. Didn't see it posted, apologies if my eyesight is bad. One can surf the citations for more related stuff. Cheers, Tuck